A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy

NCT01769547 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped Stage 1 accrual completed. Study did not proceed to Stage 2 accrual.

Conditions

Advanced Malignant Pleural Mesothelioma
MPM

Interventions

DRUG: Dovitinib

Sponsor

Ontario Clinical Oncology Group (OCOG)

Collaborators

[object Object]